Targeted Albumin Therapy Does Not Improve Short-Term Outcome in Hyponatremic Patients Hospitalized With Complications of Cirrhosis: Data From the ATTIRE Trial.
China, Louise MD, PhD 1; Freemantle, Nick PhD 2; Forrest, Ewan MD 3; Kallis, Yiannis MD, PhD 4; Ryder, Stephen D. DM 5; Wright, Gavin MD, PhD 6; O'Brien, Alastair MD, PhD 1
[Miscellaneous Article] American Journal of Gastroenterology. 116(11):2292-2295, November 2021.

(Format: HTML, PDF)

INTRODUCTION: Patients with decompensated cirrhosis and hyponatremia have a poor prognosis. We investigated Albumin to Prevent Infection in Chronic Liver Failure trial data to determine whether targeted albumin infusions improved outcome in patients with hyponatremia at baseline.

METHODS: We examined the interaction between targeted albumin and standard care for the composite primary end point, stratifying by baseline sodium >= and <130 mmol/L.

RESULTS: Randomization to albumin was associated with a significant increase in sodium; however, there was no interaction between sodium category and treatment for the trial primary end point.

DISCUSSION: Targeted intravenous albumin infusions increased serum sodium level in hospitalized hyponatremic patients with cirrhosis, but this did not improve outcome.

(C) The American College of Gastroenterology 2021. All Rights Reserved.